Hester Biosciences (HESTERBIO) | Financial Analysis & Statements
Hester Biosciences Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
841.0M
Gross Profit
616.4M
73.29%
Operating Income
186.3M
22.15%
Net Income
173.0M
20.56%
EPS (Diluted)
₹20.33
Balance Sheet Metrics
Total Assets
6.5B
Total Liabilities
3.3B
Shareholders Equity
3.3B
Debt to Equity
1.00
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Hester Biosciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3.1B | 3.0B | 2.7B | 2.4B | 2.1B |
| Cost of Goods Sold | 1.0B | 1.1B | 858.2M | 725.4M | 589.8M |
| Gross Profit | 2.1B | 1.9B | 1.8B | 1.6B | 1.6B |
| Gross Margin % | 67.0% | 63.8% | 67.7% | 69.1% | 72.5% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 350.7M | 305.1M | 316.6M | 244.4M | 206.9M |
| Other Operating Expenses | 466.0M | 430.2M | 398.3M | 290.8M | 243.8M |
| Total Operating Expenses | 816.8M | 735.3M | 714.9M | 535.2M | 450.8M |
| Operating Income | 452.4M | 422.8M | 415.6M | 564.7M | 587.6M |
| Operating Margin % | 14.5% | 13.9% | 15.6% | 24.0% | 27.4% |
| Non-Operating Items | |||||
| Interest Income | 20.4M | 19.1M | 21.7M | 19.0M | 12.9M |
| Interest Expense | 83.4M | 91.2M | 51.5M | 25.8M | 60.6M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 395.7M | 319.5M | 401.5M | 535.0M | 501.0M |
| Income Tax | 107.4M | 107.9M | 121.2M | 140.2M | 154.0M |
| Effective Tax Rate % | 27.2% | 33.8% | 30.2% | 26.2% | 30.7% |
| Net Income | 288.3M | 211.7M | 280.4M | 394.8M | 347.0M |
| Net Margin % | 9.3% | 7.0% | 10.5% | 16.8% | 16.2% |
| Key Metrics | |||||
| EBITDA | 652.0M | 575.5M | 663.2M | 745.2M | 734.8M |
| EPS (Basic) | ₹32.31 | ₹22.20 | ₹31.30 | ₹46.22 | ₹40.47 |
| EPS (Diluted) | ₹32.31 | ₹22.20 | ₹31.30 | ₹46.22 | ₹40.47 |
| Basic Shares Outstanding | 8506865 | 8506865 | 8506865 | 8506865 | 8506865 |
| Diluted Shares Outstanding | 8506865 | 8506865 | 8506865 | 8506865 | 8506865 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Hester Biosciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 55.9M | 123.1M | 126.7M | 242.7M | 208.1M |
| Short-term Investments | 9.6M | 6.9M | 11.3M | 9.5M | 2.9M |
| Accounts Receivable | 731.8M | 786.4M | 796.3M | 552.8M | 492.1M |
| Inventory | 703.8M | 755.8M | 848.1M | 753.8M | 622.2M |
| Other Current Assets | 184.7M | 204.6M | 260.2M | 950.0K | 10.4M |
| Total Current Assets | 2.0B | 2.1B | 2.3B | 1.9B | 1.6B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 59.2M | 57.9M | 53.4M | 49.1M | 57.7M |
| Goodwill | 66.6M | 39.3M | 29.4M | 20.4M | 8.5M |
| Intangible Assets | 66.6M | 39.3M | 29.4M | 20.4M | 8.5M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 25.7M | 10.0K | -400.0K | 400.0K | 10.0K |
| Total Non-Current Assets | 4.6B | 4.5B | 4.4B | 3.7B | 2.5B |
| Total Assets | 6.5B | 6.6B | 6.7B | 5.6B | 4.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 294.2M | 264.4M | 299.8M | 180.2M | 280.9M |
| Short-term Debt | 744.1M | 572.7M | 836.8M | 583.5M | 219.9M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 32.3M | 32.1M | 32.2M | 34.0M | 26.4M |
| Total Current Liabilities | 1.3B | 1.1B | 1.5B | 969.0M | 613.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.4B | 1.9B | 1.9B | 1.7B | 880.3M |
| Deferred Tax Liabilities | 59.3M | 74.1M | 73.5M | 65.1M | 72.8M |
| Other Non-Current Liabilities | 532.2M | 536.7M | 240.0M | -10.0K | -10.0K |
| Total Non-Current Liabilities | 2.0B | 2.5B | 2.3B | 2.0B | 1.1B |
| Total Liabilities | 3.3B | 3.6B | 3.8B | 2.9B | 1.8B |
| Equity | |||||
| Common Stock | 85.1M | 85.1M | 85.1M | 85.1M | 85.1M |
| Retained Earnings | 2.4B | 2.2B | 2.0B | 1.8B | 1.5B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 3.3B | 3.0B | 2.9B | 2.7B | 2.4B |
| Key Metrics | |||||
| Total Debt | 2.1B | 2.4B | 2.7B | 2.3B | 1.1B |
| Working Capital | 699.9M | 1.1B | 789.0M | 978.7M | 1.0B |
Balance Sheet Composition
Hester Biosciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 395.7M | 319.5M | 401.5M | 535.0M | 501.0M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 63.5M | 63.1M | -336.9M | -294.0M | -61.1M |
| Operating Cash Flow | 554.9M | 493.6M | 19.7M | 164.0M | 477.3M |
| Investing Activities | |||||
| Capital Expenditures | 2.7M | 550.0K | 250.0K | 1.8M | 420.0K |
| Acquisitions | - | - | 0 | -208.2M | 0 |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | 10.7M |
| Investing Cash Flow | 7.6M | 550.0K | 250.0K | -206.4M | 11.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -51.7M | -68.0M | -85.1M | -85.1M | -56.2M |
| Debt Issuance | 0 | 204.7M | 320.4M | 1.0B | 182.1M |
| Debt Repayment | -331.2M | -229.7M | -171.4M | -180.4M | -118.4M |
| Financing Cash Flow | -400.6M | -108.0M | 544.1M | 1.1B | -122.3M |
| Free Cash Flow | 439.2M | 237.4M | -541.7M | -870.0M | 173.1M |
| Net Change in Cash | 162.0M | 386.1M | 564.1M | 1.1B | 366.1M |
Cash Flow Trend
Hester Biosciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
30.37
Price to Book
3.73
Price to Sales
3.96
PEG Ratio
-1.65
Profitability Ratios
Profit Margin
12.97%
Operating Margin
17.26%
Return on Equity
8.41%
Return on Assets
4.21%
Financial Health
Current Ratio
1.44
Debt to Equity
60.85
Beta
0.22
Per Share Data
EPS (TTM)
₹48.41
Book Value per Share
₹394.06
Revenue per Share
₹368.86
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| HESTERBIO | 12.6B | 30.37 | 3.73 | 8.41% | 12.97% | 60.85 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





